387 related articles for article (PubMed ID: 18466661)
1. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.
Gauthier A; Breuer J; Carrington D; Martin M; Rémy V
Epidemiol Infect; 2009 Jan; 137(1):38-47. PubMed ID: 18466661
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.
Gialloreti LE; Merito M; Pezzotti P; Naldi L; Gatti A; Beillat M; Serradell L; di Marzo R; Volpi A
BMC Infect Dis; 2010 Aug; 10():230. PubMed ID: 20682044
[TBL] [Abstract][Full Text] [Related]
3. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK.
Matthews I; Duong M; Parsons VL; Nozad B; Qizilbash N; Patel Y; Guimicheva B
PLoS One; 2020; 15(2):e0229224. PubMed ID: 32097441
[TBL] [Abstract][Full Text] [Related]
4. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
[TBL] [Abstract][Full Text] [Related]
5. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A
Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain.
Cebrián-Cuenca AM; Díez-Domingo J; San-Martín-Rodríguez M; Puig-Barberá J; Navarro-Pérez J;
BMC Infect Dis; 2011 Nov; 11():302. PubMed ID: 22044665
[TBL] [Abstract][Full Text] [Related]
7. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
[TBL] [Abstract][Full Text] [Related]
8. Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study.
Alicino C; Trucchi C; Paganino C; Barberis I; Boccalini S; Martinelli D; Pellizzari B; Bechini A; Orsi A; Bonanni P; Prato R; Iannazzo S; Icardi G
Hum Vaccin Immunother; 2017 Feb; 13(2):399-404. PubMed ID: 27925843
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
10. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
[TBL] [Abstract][Full Text] [Related]
11. A population based study of the epidemiology of Herpes Zoster and its complications.
Weitzman D; Shavit O; Stein M; Cohen R; Chodick G; Shalev V
J Infect; 2013 Nov; 67(5):463-9. PubMed ID: 23872209
[TBL] [Abstract][Full Text] [Related]
12. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.
Curran D; Hunjan M; El Ghachi A; El-Hahi Y; Bianco V; Ferreira G
BMJ Open; 2019 Aug; 9(8):e023502. PubMed ID: 31462457
[TBL] [Abstract][Full Text] [Related]
14. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
16. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition.
Harvey M; Prosser LA; Rose AM; Ortega-Sanchez IR; Harpaz R
Pain; 2020 Feb; 161(2):361-368. PubMed ID: 31599852
[TBL] [Abstract][Full Text] [Related]
17. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV
Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y
Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601
[No Abstract] [Full Text] [Related]
18. [Burden of herpes zoster and postherpetic neuralgia: Incidence, proportion, and associated costs in the French population aged 50 or over].
Mick G; Gallais JL; Simon F; Pinchinat S; Bloch K; Beillat M; Serradell L; Derrough T
Rev Epidemiol Sante Publique; 2010 Dec; 58(6):393-401. PubMed ID: 21094001
[TBL] [Abstract][Full Text] [Related]
19. Increasing incidence associated with herpes zoster infection in British Columbia, Canada.
Marra F; Chong M; Najafzadeh M
BMC Infect Dis; 2016 Oct; 16(1):589. PubMed ID: 27765026
[TBL] [Abstract][Full Text] [Related]
20. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study.
Drolet M; Brisson M; Schmader K; Levin M; Johnson R; Oxman M; Patrick D; Camden S; Mansi JA
J Pain; 2010 Nov; 11(11):1211-21. PubMed ID: 20434957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
